UNSPSC 51422368: Prednisolone tebutate

This classification denotes a therapeutic glucocorticoid with the molecular formula C27H38O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1V7A1U282K, chemically known as pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-((3,3-dimethyl-1-oxobutyl)oxy)-, (11.beta.)-, but more generally known as prednisolone tebutate, which bears US NIH Compound Identifier 4898. European Medicines Agency schedules prednisolone tebutate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10018MIG.

Most nations, for tariff purposes, schedule prednisolone tebutate under HS 29372100. Prednisolone tebutate bears US NLM identifiers UMLS ID C0071844 and NCI Concept Code C66461. SMILES: C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COC(=O)CC(C)(C)C)O)CCC4=CC(=O)C=C[C@]34C)O.

UNSPSC 51422368 Prednisolone tebutate, a Commodity-tier code, reflects state and local procurement of injectable corticosteroid pharmaceuticals for medical and public health programs. However, the recent contract opportunities associated with this code show a significant mismatch: neither the Seminole County IFB for naloxone and drug deactivation systems nor the Texas HHS RFI for direct-to-manufacturer prescription programs involve prednisolone tebutate procurement. The Seminole County opportunity focuses on opioid-antagonist supplies and drug neutralization equipment for community health initiatives, while the Texas RFI seeks vendor capability information for a therapeutic pharmacy program structured around direct manufacturer relationships rather than specific pharmaceutical commodities. The code shows minimal relevant recent activity aligned with its stated scope.

Geographic presence is limited to what the mismatched opportunities indicate: Seminole County, Florida has issued a recent competitive procurement, and Texas HHS has initiated a market-intelligence phase for broader pharmacy program redesign. Without recent opportunities specifically tied to prednisolone tebutate procurement, the code does not support a clear characterization of state and local demand, issuing-body types, or geographic concentration. Business development professionals evaluating this code should treat it as a low-activity category and verify that their target opportunities are genuinely seeking prednisolone tebutate or closely related injectable corticosteroid products rather than relying on the posted opportunities under this UNSPSC number.